HUTCHMED (China) Limited (HCM) announced Tuesday that its experimental drug sovleplenib hit the mark in a Phase 3 trial for adults with warm antibody autoimmune hemolytic anemia, a rare blood disorder where the immune system goes rogue and starts attacking its own red blood cells.

Here's what's happening: In wAIHA, the body produces IgG antibodies that target red blood cells at normal body temperature, destroying them and causing anemia along with the usual suspects of fatigue, paleness, and shortness of breath. It's not common, affecting somewhere between 0.8 to 3.0 people per 100,000 adults annually, with prevalence hovering around 17 per 100,000 adults and a death rate of 8-11%. About three-quarters of all adult autoimmune hemolytic anemia cases fall into this warm antibody category.

The Trial Results

The China-based ESLIM-02 study enrolled adult patients with primary or secondary wAIHA who had already tried and failed at least one standard treatment. The trial met its primary endpoint: durable hemoglobin response rate between weeks 5 and 24 of treatment.

The numbers look solid. In the Phase 2 portion of the study, which was published in The Lancet Haematology in January 2025, sovleplenib showed an overall response rate of 43.8% versus 0% for placebo during the first eight weeks. Over 24 weeks of treatment, including patients who switched from placebo to the active drug, the overall response rate climbed to 66.7%. The safety profile came back favorable.

HUTCHMED is planning to submit its New Drug Application to China's National Medical Products Administration during the first half of 2026. The company is also developing sovleplenib for immune thrombocytopenia, another blood disorder, and plans to resubmit an NDA for second-line ITP treatment in the same timeframe.

The Competition Is Coming

HUTCHMED isn't operating in a vacuum here. The rare blood disorder space is getting crowded fast.

Novartis AG (NVS) released data in December 2025 from its VAYHIT2 Phase 3 trial testing ianalumab plus eltrombopag in ITP patients who had previously received corticosteroids. The results showed that patients on the Novartis combination went 2.8 times longer before treatment failure compared to placebo plus eltrombopag: 13.0 months versus 4.7 months.

Also in December, CRISPR Therapeutics AG (CRSP) kicked off a Phase 1 trial of its allogeneic CAR T therapy targeting both ITP and wAIHA. That's a different technological approach altogether, using gene-edited immune cells rather than small molecule drugs.

The fact that multiple major players are racing into this space suggests there's genuine unmet medical need here. These are serious conditions with limited treatment options, and the patient populations, while small, desperately need better therapies.

Beyond Blood Disorders

In other company news, HUTCHMED on Monday launched the Phase 3 portion of a Phase 2/3 trial combining surufatinib, camrelizumab, nab-paclitaxel, and gemcitabine as first-line treatment for metastatic pancreatic ductal adenocarcinoma in China. That's a completely different indication, showing the company's broader oncology and immunology pipeline.

Investors seem to like what they're hearing. HUTCHMED shares jumped 5.09% to $14.45 in premarket trading Wednesday following the announcement.